MODA & JAECOO Unveil 2027 “From Million To Annual Million” Strategy, Powering Chery’s Next Phase of Global Growth
Rozee Digital Helps Health and Beauty Brand Scale from $300K to $2M Per Month with Creative Strategy
Lithosphere to Launch Devnet Environment for Scalable AI Application Testing
GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing
AISIX Solutions Inc. Announces Upsize of Non-Brokered Private Placement of Shares
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model…
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the…
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy…
ERAS-3490, an orally available small molecule KRAS G12C inhibitor, has demonstrated robust nonclinical CNS and…
MISSISSAUGA, Ontario, Dec. 13, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Thursday, December 15, 2022 @ 8:00 AM ET DURHAM, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE)…
Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence…
Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD,…
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from…
Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient MORRISVILLE, N.C., Dec. 13,…
Study has enrolled over 1,800 patient samples at 4 U.S. clinical trial sites Primary endpoint…
Cellectis’ Pipeline Overview Cellectis’ Fully Owned & Licensed Product Candidate Pipeline UCART22: anti-tumor activity observed…
Cellectis’ Pipeline Overview Cellectis’ Fully Owned & Licensed Product Candidate Pipeline UCART22: anti-tumor activity observed…
Spectral to receive a significant equity stake in the joint venture, while eliminating its need…
Wave receives upfront payment of $170 million in cash and equity, also eligible to receive…
Fremont, Dec. 13, 2022 (GLOBE NEWSWIRE) — OmicsVeu, a wholly owned subsidiary of BioGenex, is pleased…
DALLAS, Dec. 13, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic”…
— Patents support Gritstone’s pioneering work in the application of next-generation samRNA vaccine technology in…
FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for…
– Positive topline data from Phase 2 study of ABP-450 for cervical dystonia announced in…